investing in biotech

The Best Biotech ETF to Buy Now

biotech stocks

There are more than 1,000 biotech companies in North America alone. They cover a wide range of sectors including pharmaceuticals, biologics, generics, and medical devices.

But finding the right stocks in such a broad industry is no easy task.

That's why we've targeted the best biotech ETF to buy now. It offers investors an excellent way to play the entire industry, without having to pick a specific sector.

Here’s the pick…

Investing in Biotech Stocks: Use This One Simple Strategy to Limit Risk and Maximize Gains

20141006-investing-in-biotech-stocks

It's a common thought that investing in biotech stocks is just too risky for the average investor - but that's not the case.

It's true that biotechnology stocks can be very volatile - especially when companies have developmental drugs going through clinical trials - so they aren't the right stocks for every investor. But when investors are able to limit risk, they can find their portfolio's biggest profits from biotech.

Money Morning's BioScience Investment Strategist Ernie Tremblay recommends investors use this one simple strategy when investing in biotech.

It helps limit risk and maximize profits. Take a look…

There Is No Biotech Bubble; Here's the Real Story

20140331_IPO-bubble

Some analysts feel that the biotech sector's recent tumble is evidence of the biotech bubble bursting.

But they're wrong; the market is simply in a period of adjustment.

The premise behind the bubble idea is that biotech companies as a group are overvalued, that their market caps aren't supported by performance. In other words, that their perceived value is all smoke and mirrors.

The problem with that argument is, these analysts are using a mass of technical indicators to support it. Anyone who's followed start-up biotechs knows that's a fool's errand.

Triple-Digit Gains… With Easy "Insurance" Against Risk

Small Cap Penny Stocks to Buy

How do single-day stock gains of 40%, 50%, 75%, even a 100% or more sound? If you're anything like me they sound pretty darn great.

Those kinds of gains happen almost every day, but the mainstream financial media would much rather focus on recent stories such as: FB jumps 14% on increased mobile revenue, GOOG rockets ahead 13% on higher top line, or TSLA up 8% on higher than expected sales of the Model S.

Small-cap biotech stocks can deliver triple-digit gains – or they can crash if clinical trial results disappoint.

Here's how to limit your losses...

The One Thing You Must Know to Hit It Big with a Biotech Stock

When you're evaluating a biotech, or even a full-fledged pharmaceutical company, you'll want to look at its product pipeline, upcoming catalysts, and financial indicators.

But the most important asset it possesses, the heartbeat that drives everything else, is its intellectual property (patent) portfolio...

That's what will make it attractive for acquisition, merger, or licensing deals.

And it's what protects its products from marauding generic drug manufacturers, who will produce copycat therapies and sell them at cutthroat prices.

For a drug development company, that spells disaster.

When a drug goes generic, it's not unusual for the original brand manufacturer's market share to drop more than 40%...

Biotech Stocks to Watch in 2014: Check Out Today's Biggest Movers

Biotech stocks have delivered a healthy dose of returns to investors year to date. The iShares Nasdaq Biotech Index ETF (Nasdaq: IBB) is up a whopping 65% so far in 2014.

That follows a 60%-plus return last year, far outpacing the 30% gain of the broader market. Some 81 biotech companies saw share prices more than double in 2013.

To continue reading, please click here...

Bypass These Pitfalls to (Major) Profits in Bioscience

Anyone who's very familiar with the bioscience/pharmaceutical sector will tell you investing in experimental drugs can be an object lesson in volatility.

As the drugs progress toward FDA approval or denial, the stock prices of the companies backing them can be in for the same volatile ride.

A stock's surge or decline is often premised on general assumptions about the likelihood of FDA approval.

But within specific bioscience sectors, that likelihood varies... widely.

That's why I wanted to navigate through some types of drugs that generate a lot of enthusiasm but often crash before delivery.

That way you can avoid some of the downside risk of this often lucrative market...

Cadence Pharmaceuticals (Nasdaq: CADX) Stock Climbs 26% in Latest Biotech Deal

Pharma

What a year so far for biotech stock profits...

Another consolidation in the active biotech sector came Tuesday when Cadence Pharmaceuticals Inc. (Nasdaq: CADX) agreed to be acquired by Mallinckrodt plc (NYSE: MNK) in a $1.3 billion deal. The move sent CADX up 26%.

Under terms of the deal, Dublin, Ireland-based Mallinckrodt will pay $14 in cash for each share of San Diego, Calif.-headquartered Cadence. That's a 26% premium to Monday's closing price and a 32% premium to the stock's average 30-day trading price.

To continue reading, please click here...

The Best Biotech Takeover Targets for 2014

cliff

This could be the biggest year ever for investing in biotech takeover targets - all due to the patent cliff.

The "patent cliff" refers to the sharp revenue drop a pharmaceutical company faces when the patent on one of its drugs expires. At that point, other drug companies can begin replicating name-brand drugs, cutting into the billions of dollars in revenue that large-cap pharmaceutical companies are used to.

To continue reading, please click here...

IPO Calendar 2014 Dominated by Biotech

best biotech investments 2014

IPO Calendar 2014: This year is forecast to be a record year for initial public offerings (IPOs).

Over the January to March period, some 250 to 300 new issues will launch, according to professional services firm EY - a number not seen since the start of the 2008 financial crisis.

And biotech companies are the hottest issues to date.

Since 2000, no two-week period saw more than six new biotech issues - until now.

See which biotech IPOs could be the best investments now...

Our Worry-Free Way of Investing in Biotech

Handsome guy with arms behind head

If there's one sector that's primed for explosive growth right now, it's biotechnology.

Its position as a new market leader in the tech sector cannot be overstated. Clearly, investing in biotech is an idea few can afford to ignore.

Genentech, the first biotech company, was formed in 1973 and was the first to go public in 1980, which launched the biotech sector.

Though the sector is only 33 years old, humans have been using varying forms of biotech for thousands of years, before anyone was investing in anything.

To continue reading, please click here...

The Best Biotech Stocks for 2013 Are Now Within Your Reach

Medical pills small

Biotech stocks are soaring in 2013 as major innovations in healthcare have offered enormous breakthroughs on once-untreatable diseases and conditions.

But for years, it was tricky to invest in some of today's best biotech companies given their volatility and uncertainty in the industry. For the better part of five years, some of today's leading biotech stocks remained essentially flat.

For some time, it was best to stick to large-scale pharmaceutical companies with a strong yield and avoid mass speculation in hit-or-miss penny stocks.

Well, not any more. Shares of the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) - which tracks industry returns - are up a staggering 42% since the beginning of the year, and the health/biotech industry has the highest returns of any sector for the year.

And you haven't seen anything yet...

With one of the most exciting biotech companies now joining the NYSE and another setting its focus on an uplisting, we're seeing major changes in the biotech industry and investment. And there are companies poised to become the best biotech stocks you can find right now.

To continue reading, please click here...

Meet the Biotech CEO With a $30 Billion Breakthrough

There's a deadly problem with one of the nation's major medical markets - vaccines.
The technology we use today to prevent diseases like the flu, chicken pox, and polio is hopelessly outdated.
It still relies on the delivery of a portion of the actual virus to the patient to develop immunity. Some of these agents are still grown in chicken eggs, just like they were back in the 1930s. And the vaccines themselves or their additives can still make people sick.
But what if you could develop a whole new class of vaccines that were actually safe using a synthetic DNA? Better yet, what if you could vaccinate yourself against HIV, cervical cancer, leukemia, and hepatitis?
The payoff would be tremendous...

The Next Profit Breakthrough: Synthetic Biology

Drug, chemical, and biofuel firms are relying more than ever on artificial fragments of DNA to invent new products. It's called synthetic biology.

For example, teams all over the world are now in their labs looking to create novel biotech compounds or drugs by inserting synthetic DNA into cells, either living or artificial. They're also growing new microorganisms that yield biofuels to be used in lieu of oil.

Trouble is, the process is so complex that it can take days to synthesize these man-made genes, usually in small batches.

Not only is it time consuming, but it requires the use of costly robots and other advanced gear. Simply stated, if someone came along with a breakthrough that greatly speeded up the development of synthetic genes, it could affect several industries at once, not to mention its own value in the market.

Allow me to introduce you to Gen9 Inc. The company is blazing a trail in the development of scalable technologies for synthesizing genes.

Now, Gen9 is a small, new dynamic company. And its potential is huge.

It was formed last summer around a unique new device that greatly speeds up the process of creating synthetic DNA.

Even better, it cuts the cost of that process by leaps and bounds.

To continue reading, please click here...

© 2014 Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201, Email: customerservice@MoneyMorning.com